Allogeneic CAR-NK Cells Therapy(Senti Bio)

异基因CAR-NK细胞疗法（Senti Bio）

Report date: 2022/06/17 16:22:40

Base Information

Drug NameAllogeneic CAR-NK Cells Therapy(Senti Bio)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionInterleukin-15 modulators

TargetsInterleukin-15

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSenti Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesSenti Biosciences Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A